CollPlant

Company Overview

Snapshot

Founded in August 2004 by Oded Shoseyov, CollPlant operates with 51–200 employees. The company has raised $93.65M across 16 funding rounds from 7 investors. In October 2025, CollPlant's rhCollagen-based BioInk demonstrated strong performance compared to Matrigel® in a study conducted by Technion - Israel Institute of Technology.

Business overview

CollPlant is a regenerative and aesthetic medicine company focused on developing technologies and products for tissue regeneration and organ manufacturing. The company's core technology leverages a plant-based approach for the mass production of recombinant human Type I collagen (rhCollagen), which is identical to human-produced collagen. This rhCollagen serves as a foundational building block for regenerative medicine applications. CollPlant utilizes the unique properties of rhCollagen and its biomaterial expertise to develop a pipeline of products for 3D bioprinting of tissues and organs, as well as medical aesthetics, serving the Health Tech & Life Sciences sector.

Strategic signal

In October 2025, CollPlant's rhCollagen-based BioInk demonstrated superior performance compared to Matrigel® in a study by Technion - Israel Institute of Technology. This validation of their proprietary bioink technology suggests significant potential for advancements in 3D bioprinting and regenerative medicine, signaling to investors a strengthening of CollPlant's competitive position and the scientific credibility of its core product offerings.

Company Intelligence Q&A

What was a significant recent scientific validation for CollPlant's technology?

In October 2025, a study conducted by Technion - Israel Institute of Technology showed that CollPlant's rhCollagen-based BioInk outperformed Matrigel®, a leading extracellular matrix, in performance.

What recent development occurred regarding CollPlant's rhCollagen distribution in North America?

In November 2025, CollPlant announced an expansion of its rhCollagen and BioInk raw material sales in North American territories through a new partnership with a U.S.-based logistics center.

What was the outcome of non-clinical studies for CollPlant's photocurable regenerative dermal and soft tissue filler?

In September 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler.

What was a key development in 3D bioprinting research using CollPlant's rhCollagen-based BioInk?

In October 2025, Mayo Clinic researchers developed a first-in-kind fully humanized 3D bioprinted human skin model using CollPlant's rhCollagen-based BioInk, designed as an alternative to animal testing for preclinical research.

When did CollPlant expand the distribution of its VergenixSTR product in Europe?

In September 2025, CollPlant expanded the distribution of its VergenixSTR product in Europe.